Skip to main content

Loading market data...

AMRX

Amneal Pharmaceuticals, Inc.

NASDAQ • United states

$19.44

+$0.08

(+0.39%)

Source: Yahoo Finance · Quote time Oct 20, 2026 13:47 GMT+0000

Management
Credibility
Score

Amneal Pharmaceuticals, Inc. (AMRX)

Unavailable

Quotes may be delayed

$6.77B

Market Cap

145,263

Volume

43.0

P/E Ratio

Unavailable

Div Yield

Amneal Pharmaceuticals, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: Not disclosed
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

12 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Amneal Pharmaceuticals, Inc..

12 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Amneal Pharmaceuticals, Inc..

12 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Amneal Pharmaceuticals, Inc..

10 Aug 2026

Amneal Pharmaceuticals, Inc. reported A material agreement

Amneal Pharmaceuticals, Inc. filed an 8-K covering a material agreement, an acquisition or sale of significant assets, a material financing obligation, an unregistered sale of shares, Regulation FD disclosure, supporting financial statements or exhibits.

6 Aug 2026

Amneal Pharmaceuticals, Inc. filed Form 10-Q

Amneal Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$127.64M

Total assets (USD)$3.78B

Total liabilities (USD)$0

Shareholders' equity (USD)$33.02M

Long-term debt (USD)$2.56B

Debt due within a year (USD)$5.96M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$796.20M	$129.77M	$57.66M	$0.18	10-Q · 6 Aug 2026
Q1 2026	$722.52M	$141.77M	$62.26M	$0.19	10-Q · 7 May 2026
Q4 2025	$814.32M	$112.03M	$35.08M	Unavailable	10-K · 27 Feb 2026
Q3 2025	$784.51M	$70.34M	$2.37M	$0.01	10-Q · 6 Nov 2025
Q2 2025	$724.51M	$111.37M	$22.42M	$0.07	10-Q · 7 Aug 2025
Q1 2025	$695.42M	$100.35M	$12.20M	$0.04	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $23.20

19.4% upside potential

📈

Strong Buy

Unavailable

👍

Buy

6

⏸️

Hold

0

📉

Sell

0

6 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 13:48 UTC Targets range 20.00–27.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

17

Sep 2026

BUCHI J KEVIN

Director

Gift

Unavailable per share

20,445 shares

11

Sep 2026

BUCHI J KEVIN

Director

Option exercise

$14.45 per share

20,445 shares

1

Sep 2026

BOYER ANDREW S

Executive Vice President

Gift

Unavailable per share

80,000 shares

21

Aug 2026

BOYER ANDREW S

Executive Vice President

Gift

Unavailable per share

152,426 shares

13

Aug 2026

Kiely John

Director

Open-market sale

$17.64 per share

50,000 shares

13

Aug 2026

Kiely John

Director

Gift

Unavailable per share

10,000 shares

12

Aug 2026

Shah Nikita

Executive Vice President

Open-market sale

$17.51 per share

146,403 shares

12

Aug 2026

Daly Jason B.

EVP, Chief Legal Officer

Open-market sale

$17.40 per share

210,000 shares

11

Aug 2026

Daly Jason B.

EVP, Chief Legal Officer

Open-market sale

$17.70 per share

6,613 shares

11

Aug 2026

BUCHI J KEVIN

Director

Option exercise

$17.18 per share

168,573 shares

Top Shareholders

Blackrock, Inc.

26,562,093 shares

8.332% change

6/30/2026

Vanguard Group Inc

17,907,815 shares

-0.263% change

12/31/2025

Tpg Gp A, Llc

12,328,767 shares

0% change

6/30/2026

Vanguard Portfolio Management Llc

12,137,727 shares

7.177% change

6/30/2026

Rubric Capital Management Lp

10,168,660 shares

-7.872% change

6/30/2026

Vanguard Capital Management Llc

7,710,126 shares

1.649% change

6/30/2026

State Street Corp

7,356,977 shares

8.275% change

6/30/2026

Dimensional Fund Advisors Lp

5,794,263 shares

1.822% change

6/30/2026

Geode Capital Management, Llc

5,139,449 shares

13.053% change

6/30/2026

Morgan Stanley

4,110,028 shares

-11.368% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 13:48 UTC· 1 day ago

Research coverage and investment tools

Amneal Pharmaceuticals, Inc. (AMRX) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$19.44 on 20 Oct 2026. That is 84% of the way from its 52-week low of US$9.99 to its 52-week high of US$21.18. Its market capitalisation was US$6.77 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$796.20M	$129.77M	$57.66M	$0.18	42.0%	16.3%	−$51.94M	10-Q · 6 Aug 2026 (opens in a new tab)
Q1 2026	$722.52M	$141.77M	$62.26M	$0.19	44.3%	19.6%	−$34.92M	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$814.32M	$112.03M	$35.08M	Unavailable	36.5%	13.8%	$108.54M	10-K · 27 Feb 2026 (opens in a new tab)
Q3 2025	$784.51M	$70.34M	$2.37M	$0.01	34.9%	9.0%	$106.15M	10-Q · 6 Nov 2025 (opens in a new tab)
Q2 2025	$724.51M	$111.37M	$22.42M	$0.07	39.5%	15.4%	$60.99M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$695.42M	$100.35M	$12.20M	$0.04	36.8%	14.4%	−$5.75M	10-Q · 7 May 2025 (opens in a new tab)

Cash and equivalents: $127.64M
Total assets: $3.78B
Total liabilities: $0
Shareholders' equity: $33.02M
Long-term debt: $2.56B
Debt due within a year: $5.96M

SCHEDULE 13D/A · 12 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Amneal Pharmaceuticals, Inc..
SCHEDULE 13D/A · 12 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Amneal Pharmaceuticals, Inc..
SCHEDULE 13D/A · 12 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Amneal Pharmaceuticals, Inc..
8-K · 10 Aug 2026 · Merger or acquisition Completed

Amneal Pharmaceuticals, Inc. reported A material agreement (opens in a new tab)

Amneal Pharmaceuticals, Inc. filed an 8-K covering a material agreement, an acquisition or sale of significant assets, a material financing obligation, an unregistered sale of shares, Regulation FD disclosure, supporting financial statements or exhibits.
10-Q · 6 Aug 2026

Amneal Pharmaceuticals, Inc. filed Form 10-Q (opens in a new tab)

Amneal Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

Insider	Date	Transaction	Shares	Average price	Filing
BUCHI J KEVIN Director	17 Sep 2026	Gift (G)	−20,445	—	Form 4 (opens in a new tab)
BUCHI J KEVIN Director	11 Sep 2026	Option exercise (M)	+20,445	$14.45	Form 4 (opens in a new tab)
BOYER ANDREW S Executive Vice President	1 Sep 2026	Gift (G)	−80,000	—	Form 4 (opens in a new tab)
BOYER ANDREW S Executive Vice President	21 Aug 2026	Gift (G)	−152,426	—	Form 4 (opens in a new tab)
Kiely John Director	13 Aug 2026	Open-market sale (S)	−50,000	$17.64	Form 4 (opens in a new tab)
Kiely John Director	13 Aug 2026	Gift (G)	−10,000	—	Form 4 (opens in a new tab)
Shah Nikita Executive Vice President	12 Aug 2026	Open-market sale (S)	−146,403	$17.51	Form 4 (opens in a new tab)
Daly Jason B. EVP, Chief Legal Officer	12 Aug 2026	Open-market sale (S)	−210,000	$17.40	Form 4 (opens in a new tab)
Daly Jason B. EVP, Chief Legal Officer	11 Aug 2026	Open-market sale (S)	−6,613	$17.70	Form 4 (opens in a new tab)
BUCHI J KEVIN Director	11 Aug 2026	Option exercise (M)	−168,573	$17.18	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	26,562,093	8.332%
Vanguard Group Inc	12/31/2025	17,907,815	-0.263%
Tpg Gp A, Llc	6/30/2026	12,328,767	0%
Vanguard Portfolio Management Llc	6/30/2026	12,137,727	7.177%
Rubric Capital Management Lp	6/30/2026	10,168,660	-7.872%
Vanguard Capital Management Llc	6/30/2026	7,710,126	1.649%
State Street Corp	6/30/2026	7,356,977	8.275%
Dimensional Fund Advisors Lp	6/30/2026	5,794,263	1.822%
Geode Capital Management, Llc	6/30/2026	5,139,449	13.053%
Morgan Stanley	6/30/2026	4,110,028	-11.368%

Previous close: 19.36 USD
Day range: 19.31 – 19.64 USD
52-week range: 9.99 – 21.18 USD
Volume: 145,263
Market cap: $6.77B
Average volume: 2,713,715
P/E ratio: 43.0
EPS (FY 2025, diluted): 0.22 USD
Shares outstanding: 348.30M
Beta (5Y monthly): 1.22

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 13:47 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:17 UTC· 56 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for AMRX yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.